imaging of solid tumors using fap-2286

Conditions: Solid Tumors, Adult; Metastatic Cancer

Summary: this is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68ga-) or copper 64 (64cu-) fap-2286 tracer. fap-2286 is a peptidomimetic molecule that that binds to fibroblast activation protein (fap). fap is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.

initially the investigator(s) will focus on imaging breast, pancreas, sarcoma, prostate cancer, bladder cancer, colon cancer, and head and neck cancer. study aims 1. determine the dosimetry for gallium-68 labelled (68ga-) and 64cu- fap-2286. 2. evaluate the uptake and retention of radiotracer in a variety of solid tumors with fap-2286. 3. evaluate the ability of fap-2286 to detect metastatic disease. primary objectives 1. all cohorts: safety of 68ga- and 64cu-fap-2286. 2. cohort 1a: determine the organ dosimetry of 68ga-fap-2286. 3. cohort 1b: determine the organ dosimetry of 64cu-fap-2286. 4. cohort 2: to assess the feasibility of detecting tumor uptake using fap-2286. 5. cohort 3: to determine the feasibility of detecting metastatic disease using fap-2286. exploratory objectives 1. to detect the sensitivity of fap-2286 pet compared to conventional imaging for the detection of metastatic disease, and when available sensitivity compared to fluorodeoxyglucose (fdg) pet (fdg-pet). 2. correlation of fap-2286 uptake with fap expression determined by immunohistochemistry. 3. compare biodistribution of 68ga-fap-2286 and 64cu-fap-2286 in normal organs and blood pool based on renal function. 4. determine impact of administered dose of fap-2286 on image quality. 5. compare the feasibility of detecting tumor uptake using 68ga-fap-2286 and 64cu-fap-2286 a repeat radiolabeled fap-2286 pet may be obtained after initiation of subsequent treatment in order to evaluate changes in pet uptake due to treatment effect. patients will be followed for up to 3 days after the injection of radiolabeled ligand for evaluation of adverse events.

Eligibility criteria:
inclusion criteria: 1. age \>= 18 years 2. histopathologically confirmed solid tumors in one of the following cohorts: a. cohort 1 (n=16): measurable disease is not required for this cohort. i. agnostic to tumor type. b. cohort 2 (n=40): metastatic disease present on conventional imaging defined as having recist 1.1 measurable disease or multiple bone metastases. i. pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, or colon cancer. ii. pathologically confirmed cancer other than noted above (basket subgroup, n=10). c. cohort 3 (n=30): no evidence of metastatic disease as defined as the absence of recist 1.1 measurable disease or bone metastases. i. patients can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. patients may also be imaged after definitive therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and/or prognosis. ii. pathologically confirmed head and neck cancer or bladder cancer. 3. ability to understand a written informed consent document, and the willingness to sign it. exclusion criteria: 1. unlikely to comply with protocol procedures, restrictions and requirements and judged by the investigator to be unsuitable for participation. 2. known pregnancy.

Keywords: pet 68ga-fap-2286 64cu-fap-2286